Innovative Pain Relief through Liposomal CBD
This promising development marks Innocan Pharma Corporation's second successful application of their Liposomal CBD injection (LPT-CBD), paving the way for both veterinary and potential human medical use.
Ariel's Journey to Recovery
Ariel, a 35-year-old female donkey, had been struggling with severe osteoarthritis resulting in limited mobility and chronic pain. As part of a compassionate care initiative, she received a single dose of Innocan’s LPT-CBD injection, which surprisingly improved her mobility. After a period of noticeable improvement, a second injection was administered, further enhancing her condition.
Observations from Treatment
Prof. Chezy Barenholz, head of Innocan Pharma's Scientific Advisory Board, commented on the treatment outcomes, stating, "Innocan's Liposomal CBD shows a significant potential in not only managing pain but also improving the quality of life for animals in pain, as evidenced in Ariel's case. The results, coupled with past trials in other large animals, suggest that LPT-CBD may offer viable solutions for pain management in veterinary medicine."
Expanding Horizons: Beyond Veterinary Applications
Innocan Pharma's LPT-CBD not only shows promise for animal treatment but has also made noteworthy progress towards human applications. Dr. Eyal Kalo, the R&D Director at Innocan, shared, "We have had successful pre-IND meetings with regulatory authorities, highlighting LPT-CBD’s potential as a non-opioid alternative for chronic pain management in humans. This phase of trials is tremendously exciting as we seek to develop safer options for pain relief." Furthermore, the insights gained from treatments on animals suffering from natural diseases bolster the case for LPT-CBD's beneficial effects.
The Science Behind LPT-CBD
LPT-CBD is an innovative injectable formulation designed for the sustained release of synthetic CBD. Its unique formulation is tailored to address chronic pain, proving beneficial for both humans and animals alike. As research and trials progress, Innocan aims to improve the drug-delivery technology for enhanced efficacy.
About Innocan Pharma Corporation
Innocan Pharma stands at the forefront of pharmaceutical innovation. Their groundbreaking development involves a CBD-loaded liposome drug delivery platform capable of controlled release for effective pain management without the reliance on opioids. Beyond pharmaceuticals, Innocan actively markets a diverse portfolio of wellness products targeting self-care and beauty, thereby promoting overall well-being. Their subsidiary, BI Sky Global Ltd., ventures into advanced online sales, enhancing accessibility to quality wellness products.
Contact Information
If you would like to learn more about Innocan Pharma and its innovative treatments, please reach out to:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
Frequently Asked Questions
What is Innocan's Liposomal CBD injection used for?
The Liposomal CBD injection is designed for pain relief in both veterinary and potential human applications, particularly for chronic pain management.
How did Ariel benefit from the LPT-CBD treatment?
Ariel, the elderly donkey, experienced significant mobility improvements and pain relief following the administration of the LPT-CBD injection.
What are the future plans for LPT-CBD in human medicine?
Innocan plans to pursue clinical trials for LPT-CBD as a non-opioid alternative for chronic pain in humans, building on its success in veterinary medicine.
What is the significance of the second LPT-CBD injection?
The second injection demonstrated that the effects of the treatment could be sustained and further improved, indicating strong therapeutic potential.
How does Innocan Pharma's approach differ from traditional pain management?
Innocan offers a non-opioid solution through its unique drug delivery system, aiming to provide effective pain relief without the risks associated with opioid medications.
